For the year ending 2025-12-31, GOSS had -$8,342K decrease in cash & cash equivalents over the period. -$171,345K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -170,370 |
| Depreciation and amortization | 24 |
| Stock-based compensation expense | 10,555 |
| In process research and development expenses | 7,475 |
| Amortization of operating lease right-of-use assets | 978 |
| Amortization of long-term debt discount and issuance costs | 985 |
| Amortization of premium on investments, net of accretion of discounts | 7,278 |
| Net realized gain on investments | 5 |
| Loss on disposal of property and equipment | 0 |
| Receivable from contracts with collaborators | 6,889 |
| Prepaid expenses and other current assets | 8,453 |
| Other assets | 125 |
| Operating lease liabilities | 961 |
| Accounts payable | -2,747 |
| Accrued expenses | 1,448 |
| Accrued research and development expenses | 11,207 |
| Accrued compensation and benefits | -784 |
| Contract liabilities | -6,326 |
| Accrued interest expense | 0 |
| Net cash used in operating activities | -171,266 |
| Purchase of marketable securities | 227,107 |
| Maturities of marketable securities | 376,400 |
| Sales of marketable securities | 7,144 |
| Purchase of property and equipment | 79 |
| Net cash provided by (used in) investing activities | 156,358 |
| Proceeds from issuance of common stock and warrants in a private offering, net of offering costs | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | 840 |
| Proceeds from the exercise of stock options | 1,930 |
| Proceeds from the exercise of warrants | 3,655 |
| Proceeds from issuance of equity option pursuant to stock purchase agreement | 0 |
| Principal repayments of long-term debt | 0 |
| Net cash provided by (used in) financing activities | 6,425 |
| Effect of exchange rate changes on cash and cash equivalents | 141 |
| Net increase (decrease) in cash and cash equivalents | -8,342 |
| Cash and cash equivalents, at the beginning of the period | 46,074 |
| Cash and cash equivalents, at the end of the period | 37,732 |
Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. (GOSS)